LLY's recent sell-off presents a buying opportunity for savvy investors, with strong growth potential in the GLP-1 market ...

After flying high during the first half of the year, pharmaceutical giant Eli Lilly (NYSE: LLY) has lost some momentum; the ...

We recently compiled a list of the Jim Cramer on Nvidia Plus Other Stocks. In this article, we are going to take a look at ...

The drugmaker looks to rein in how it gives discounts in a federal program designed to help hospitals that serve low-income ...

French drugmaker Sanofi plans to change its policy on how it gives discounts to certain U.S. hospitals that serve low-income ...

Sarrah Strimel Bentley is an optimist – even when it comes to her journey with early breast cancer. The new mother and philanthropist discusses why she’s empowered to live a happy and healthy life.

We recently made a list of Goldman Sachs’ Top Growth Investors: 34 Stocks With The Highest Investment For Growth.

French pharma company Sanofi has joined Ely Lilly and Johnson & Johnson in a challenge to the U.S.'s 340B drug discount ...

The Food and Drug Administration told a federal judge Thursday that it needs more time to reconsider whether Eli Lilly blockbuster GLP-1 drugs Zepbound and Mounjaro are in shortage. Shares of the ...

The Players Era Festival, which will be held in Las Vegas next week, is set to announce a presenting sponsor lineup or Eli Lilly Company, MGM Resorts, and Starbucks.

Eli Lilly faces challenges with slowing drug sales and a lawsuit against the HRSA. Learn why caution is advised for LLY stock despite its lower P/E ratio.

According to Reuters and CNN, Novo Nordisk announced Monday that it has launched its popular obesity drug Wegovy in China, ...